



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAY 02 2003

TECH CENTER 1600/2900

In re application of:

Zauderer *et al.*

Appl. No. 09/987,456

Filed: November 14, 2001

For: ***In Vitro* Methods of Producing
and Identifying Immunoglobulin
Molecules in Eukaryotic Cells**

Confirmation No. 6770

Art Unit: 1627

Examiner: Venkat, J.

Atty. Docket: 1821.0070004/EKS/EJH/T-M

Second Supplemental Information Disclosure Statement

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' First Supplemental Information Disclosure Statement filed on November 6, 2002, and Applicants' Information Disclosure Statement filed on May 28, 2002, in connection with the above-captioned application. A copy of each document is also provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates

should not be construed as an admission that the information was actually published on the date indicated.


This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.


Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

 # 36688
Elizabeth J. Haanes, Ph.D., Esq.
Agent for Applicants
Registration No. 42,613

Date: 5/1/03

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600



RECEIVED

MAY 02 2003

TECH CENTER 1600/2000

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1821.0070004/EKS/EJH/T-M	APPLICATION NO. 09/987,456
	APPLICANT Zauderer et al.	
	FILING DATE November 14, 2001	GROUP 1627


U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC3	5,830,721	11/03/1998	Stemmer et al.			03/04/1996
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN8	WO 99/30151 A1	06/17/1999	WIPO			Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
AR	34	Griffiths, A.D., et al., "Isolation of high affinity human antibodies directly from large synthetic repertoires," <i>EMBO J.</i> 13:3245-3260, Oxford University Press (1994).	
AS	34	Smith, E.S., et al., "Lethality-based selection of recombinant genes in mammalian cells: Application to identifying tumor antigens," <i>Nat. Med.</i> 7:967-972, Nature Publishing Company (August 2001).	
AT	34	Waterhouse, P., et al., "Combinatorial infection and <i>in vivo</i> recombination: a strategy for making large phage antibody repertoires," <i>Nucl. Acids Res.</i> 21:2265-2266, Oxford University Press (1993).	

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED
MAY 02 2003
TECH CENTER 1600/2900

Page 2 of 2

FORM PTO-1449
SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1821.0070004/EKS/EJH/T-M

APPLICATION NO.
09/987,456

APPLICANT
Zauderer et al.

FILING DATE
November 14, 2001

GROUP
1627

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>35</u>	International Search Report for International Patent Application No. PCT/US)1/43076, mailed April 1, 2003.
	AS		
	AT		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.